TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04024904

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncomfortTM device
Description: The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OncomfortTM device
Description: The VHRD (Virtual Reality Hypnosis Distraction) technique is the program of OncomfortTM (Oncomfort Inc, Houston, USA). The OncomfortTM device include the hyper vision 3D virtual reality glasses and disposable single-patient-use headphones. The program is an immersive experience focused on inducing relaxation environment and this program exist in 5,15 and 30 minutes
Study: NCT00299013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone 40mg oral tablets, once daily, dose tapering weekly (40,40,30,20,15,10,5,0mg) over 8 weeks.
Study: NCT03349866

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: apatinib
Description: apatinib：250mg qd po

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 1000mg/m2 bid d1-14

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000mg/m2 bid d1-14

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: 130 mg/m2 Ivgtt d1 q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 130 mg/m2 Ivgtt d1 q3w
Study: NCT00809627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine 500 mg IV
Study: NCT03349866

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 45Gy/25f （1.8Gy/f/d，5 f/w）

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 45Gy/25f （1.8Gy/f/d，5 f/w）
Study: NCT03926962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: WCK 4873
Description: 100 to 1200 mg in tablets (the 100 mg dose cohort will receive half a tablet; higher dose cohorts will receive 1 or more tablets)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Visually matching placebo
Study: NCT00868673

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: low fructose
Description: patients will receive a low fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). low fructose arm: a 2 week period of low fructose diet (less than 10 grams/day ) followed by a 4 week period of healthy fructose diet levels (less than 20 grams/day).Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normal fructose arm
Description: patients will receive a normal fructose diet to evaluate possible changes in weight loss after a 6 week period of receiving a caloric intake (proteins, fats and carbohydrates) based on their healthy-desired weight. Participants will be randomized to a 1500, 1800 or 2000 kilocalories diet calculated by Harris Benedict equation, thermic effect of foods and energy (without exercise). Normal fructose arm: participants will receive a 6 week period of normal fructose diet between 50 to 70 grams/day. Baseline measurements and weekly monitoring of somatometry parameters (BMI, %body fat, waist and hip Index, blood pressure), lipid profile and uric acid levels will be done.
Study: NCT04852510

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Versus a combination of Metformin and Thymoquinone (TQ)
Description: Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin Versus a combination of Metformin and Thymoquinone (TQ)
Description: Patients were divided into two groups (A and B) using a computer-based software Open Epi version 3.21. Patients in Group A, received Metformin 500 mg three times daily (5) with meals for 6 months (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA). Patients in Group B, received a combination of Metformin 500 mg three times daily with meals (Metfor® 500 mg, Metformin hydrochloride tablets. TABUK Pharmaceutical. KSA) and Thymoquinone (TQ) in the form of Black Cumin oil (Cumin Mar® Black cumin oil 500 mg soft gel capsules, MARNYS. Spain) three times daily before meals for 6 months.
Study: NCT04254874

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abidol hydrochloride
Description: 0.2g once, 3 times a day,two weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abidol Hydrochloride combined with Interferon atomization
Description: Abidol Hydrochloride:0.2g once, 3 times a day,two weeks; Interferon(PegIFN-α-2b) atomization:45ug, add to sterile water 2ml, twice a day,two weeks
Study: NCT05008250

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongmai Yangxin Pill (TMYXP)
Description: TMYXP is a Chinese patent medicine developed by many years of clinical practice experience. The ingredients of TMYXP are Radix Rehmanniae, Caulis Spatholobi, Polygonum Multiflorum, Colla Corii Asini, Ophiopogonis, Tortoise Shell (vinegar), Radix Codonopsis, Cassia Twig, Jujube, Schisandra Fruit, and Licorice Root. It has the effect of invigorating Qi, nourishing Yin, dredging the pulse, and relieving pain. It is used in treatment of Qi and Yin deficiency syndromes caused by coronary heart disease, angina pectoris, and arrhythmia.~Metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.
Study: NCT02008409

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EndoLift Liver Retractor
Description: During the surgery, the surgeon will use the new internal liver retractor device. The device will retract the liver out of the way and help the surgeon see better during the surgery. The device is placed inside the abdomen during the surgery. It is clipped onto 2 safe surfaces inside the abdomen. The device is removed before the surgery ends.
Study: NCT01498185

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 1 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 1 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 1 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin
Description: Tablets, Oral, 1 mg, Once daily, 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo matching Dapagliflozin
Description: Tablets, Oral, 0 mg, Once daily, 14 days
Study: NCT00946322

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Couple-Based Treatment for Alcohol Use Disorders and PTSD
Description: This intervention includes cognitive-behavioral strategies for helping couples to reduce alcohol use and PTSD, while improving relationship functioning.
Study: NCT02559661

Intervention type: OTHER
Intervention: Training on a virtual simulator in eye surgery
Study: NCT00809627

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: saline
Description: Normal saline
Study: NCT03663361

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SMART Intervention
Description: Ankle rehabilitation with the addition of sensorimotor components

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Intervention
Description: Ankle rehabilitation focused on restoring range of motion, strength and balance
Study: NCT04531345

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers

Intervention type: DIAGNOSTIC_TEST
Intervention: Flow cytometric analysis
Description: IL-1β, IFN-α2, IFN-γ, TNF-α, MCP-1 (CCL2), IL-6, IL-8 (CXCL8), IL-10, IL-12p70, IL-17A, IL-18, IL-23, IL-33 cytokine analysis of COvid-19 patients and healthy volunteers
Study: NCT02709239

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: DHA 200mg
Description: 4 50mg capsules of DHA to be taken by mouth daily

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA 800mg
Description: 4 200mg capsules of DHA to be taken by mouth daily
Study: NCT04006821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib mesylate
Description: Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
Study: NCT02559661

Intervention type: OTHER
Intervention: Training on a virtual simulator in eye surgery

Intervention type: OTHER
Intervention: Training on a virtual simulator in eye surgery
Study: NCT03205904

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Nutrition booklet with guidelines on types of fats and glycemic index
Study: NCT05008250

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: metoprolol tartrate
Description: metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metoprolol tartrate
Description: metoprolol tartrate (a heart-selective β-blocker) is a class II antiarrhythmic medication that decreases the ventricular rate of supraventricular tachyarrhythmias by inhibition of atrioventricular conduction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: simulated pills
Study: NCT02577211

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Hipocaloric enteral nutrition
Description: 15 kcal/Kg of body weight

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Normocaloric enteral nutrition
Description: 25 kcal/kg of body weight
Study: NCT03889548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mental Imagery
Description: Immediately after determination of the resting motor threshold and pre-test measurements, the TMS administrator will leave the room so as to be blinded to the treatment condition of the participant. At this time the participant will be given instructions regarding the mental imagery protocol from a separate investigator who will not be blinded to the condition. During the mental imagery protocol, participants will be instructed to close their eyes and imagine they are maximally contracting the muscles in their forearm and imagine that they are making their wrist flex and that they are pushing maximally against a hand grip in their hand. This will be a kinesthetic imagery task, in which they are urging their muscles to contract maximally.
Study: NCT04660227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Exercise Trainning
Description: Participants in the online exercise program group will be given a treatment protocol consisting of aerobic exercise and strengthening exercises in the presence of a physiotherapist for a total of 8 weeks, 2 days a week for 1 hour. Before starting the exercise, the risk of possible injury will be minimized by doing warm-up exercises and preparations will be made to start the exercise. Then, the exercise program will be started with aerobic exercise. Strengthening exercises will be planned for large muscle groups, targeting body parts such as hips, knees, shoulders, abdomen and trunk. In exercises, it is planned to do 2 sets of 10-15 repetitions using elastic band, free weights or body weight. The exercise program will be created according to the condition of the people and progression will be provided every 2 weeks. After the exercises are completed, cool down will be done with relaxation and stretching exercises.

Intervention type: OTHER
Group type: OTHER
Intervention: Control Group
Description: Participants in the control group will be put on the waiting list after all assessment methods have been applied and will be re-evaluated at the end of 8 weeks. After the final evaluations, they will be directed to the exercise group.
Study: NCT02087527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: IV Dexamethasone 0.15 mg/kg every 6 hours for 48 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IV normal saline every 6 hours for 48 hours
Study: NCT01755884

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wheat oral immunotherapy
Description: Cooked spaghetti
Study: NCT01019642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cholecalciferol
Description: 4,000 IU per day during 6 months. Capsule form.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: no active principles given.
Study: NCT00849602

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo bid for three days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chloroquine
Description: Chloroquine bid for three days
Study: NCT02986100

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C-14 labeled Rucaparib
Description: Each dosage unit consists of a hard gelatin capsule filled with cold rucaparib camsylate and \[14C\]-rucaparib camsylate salt. Each capsule contains approximately 150 mg rucaparib (free base weight) and approximately 35 µCi of \[14C\]-rucaparib. Each patient will ingest four capsules in the fasted state for a total dose of 600 mg rucaparib (free base weight) with approximately 140 µCi of \[14C\]-rucaparib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rucaparib
Description: 200 \& 300 mg tablet
Study: NCT04079543

Intervention type: OTHER
Group type: OTHER
Intervention: NPO past midnight
Description: NPO after midnight (solids and liquids), except for a sip of water with medication.

Intervention type: OTHER
Group type: OTHER
Intervention: NPO
Description: No solids after midnight. Clear liquids up to 2 hours prior to procedure. Patients can take medications with a sip of water.
Study: NCT03514498

Intervention type: PROCEDURE
Intervention: Dental surgery
Description: All types of dental surgery

Intervention type: PROCEDURE
Intervention: Dental surgery
Description: All types of dental surgery
Study: NCT02386904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phosphate Enema (Kleen® Enema)
Description: 120ml (single bottle) administered via rectal route before 30min of sigmoidoscopy .
Study: NCT01526616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin 850 mg twice a day for six months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin plus Spironolactone
Description: Metformin 850 mg twice a day for six months plus Spironolactone 25 mg day
Study: NCT03070574

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine 2400 MG (5-ASA)
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers, each 1200mg of IMP (= 2400 mg), every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mesalamine 1200 MG
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (1200 mg/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: For this study IMP will be supplied as film-coated tablets packed in containers. Each patient will receive two different containers of IMP (placebo/placebo) every 3 months (± 1 week), 100 tablets per container. The containers will be marked in different colours, to prevent the patients from taking two tablets from one container accidentally.
Study: NCT02202642

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: collagenase
Description: Cultured limbal stem cells transplantation
Study: NCT00388726

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Physician's Choice
Description: Treatment of the Physician's Choice defined as any single agent chemotherapy, hormonal treatment or biological therapy approved for the treatment of cancer; or palliative treatment or radiotherapy, administered according to local practice, if applicable.
Study: NCT02584257

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methacholine chloride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: methacholine chloride

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: methacholine chloride

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: methacholine chloride

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: methacholine chloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo ProAir HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo ProAir HFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo ProAir HFA

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo ProAir HFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir HFA

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ProAir HFA

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupin albuterol HFA MDI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lupin albuterol HFA MDI
Study: NCT04179695

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Consulting with PARKINSUN as communication aid-tool
Description: Participating patients visit their general practitioner or neurologist with PARKINSUN at 1 months, 4 months, 7 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Consulting without PARKINSUN as communication aid-tool
Description: Participating patients visit their general practitioner or neurologist without PARKINSUN at 1 months, 4 months, 7 months
Study: NCT01251549

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ReWalk - a motorized exoskeleton suit
Description: The subject will wear the ReWalk suit and have training sessions for walking with the device
Study: NCT03933150

Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound guided caudal epidural injection
Description: A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor

Intervention type: DEVICE
Group type: OTHER
Intervention: ultrasound guided caudal epidural injection
Description: A. Ultrasound-Guided CESI (Group 1) All the injection procedures were performed as an outpatient clinic setting. We used Acuson P300 (Siemens, Italy) with a linear transducer at 6 to 12 MHz as the US instrument, another curved transducer at 2-5 MHz was available for obese patients.~B. Fluoroscopy-Guided CESI (Group 2) All the injection procedures were performed in a specialized room with a FL device in the radiology department. We used a FL device GS 1004 with ALLURA XPER FD 20 system (Philips, Holland) with X-ray tube housing assembly, X-ray tube, beam limiting device and image receptor
Study: NCT00947973

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP) after-school model
Description: Interventions delivered by a counselor 2 days a week as an after-school program. Interventions will strengthen skills in materials organization, homework management, studying, note taking, and socialization.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Challenging Horizons Program (CHP) consultation model
Description: Interventions delivered by a mentor (e.g., a teacher or school counselor) as needed, with expert consultation available